N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder

Author(s): Fabiele M. Fritzen, Michael H. Bloch

Journal Name: Current Psychiatry Reviews
Continued as Current Psychiatry Research and Reviews

Volume 10 , Issue 4 , 2014


Many children and adults with Obsessive-Compulsive Disorder experience incomplete symptom relief despite treatment with several evidence-based interventions for OCD. Converging lines of evidence from genetic, neuroimaging, biochemical and pharmacological studies implicate the importance of abnormalities in the glutamate symptoms in the pathogenesis of OCD. Strong evidence suggests that oxidative stress may be important in the progression of several psychiatric disorders, especially psychotic and affective disorders. N-acetylcysteine (NAC) is a cheap, relatively safe over-the-counter supplement that crosses the blood-brain barrier and acts potentially as a glutamate modulating agent and antioxidant. NAC has demonstrated efficacy in the treatment of a wide variety of psychiatric conditions in individual randomized, controlled trials including psychosis, autism, bipolar depression, trichotillomania. A recent double-blind placebo-controlled in adults with SRI-refractory OCD demonstrated the efficacy of NAC compared to placebo. In this review we summarize the preclinical and clinical data demonstrating NAC is a potentially promising new pharmacological agent in the treatment of OCD.

Keywords: Glutamate, n-acetylcysteine, obsessive-compulsive disorder, oxidative stress, review, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 05 November, 2014
Page: [308 - 316]
Pages: 9
DOI: 10.2174/1573400510666140807005327
Price: $58

Article Metrics

PDF: 29